Antibe Therapeutics Inc(Pre-Merger) ATBPF

Bristol ...

[MrMugsy]

BMS is in a tough spot - as with a few other Big Pharmas and their patent cliff situation out to 2030.
There will be lots of desire to acquire or partner with good companies over the next few years.

For example ... if we just look at BMS, they have three drugs coming off patent

Revlimid (2026), Eliquis (2029) - partnered with Pfizer ... and ... Opdivo (2028).
Revenues totaling  $28.3B/year (including Pfizer's portion of Eliquis).

We seem to be on the right side of needed acquisitions to shore up revenue losses from patent expirations and if we prove ourselves ... there will be gold at the end of the rainbow.

That's why a successful acute run is important - why a chronic solution (during P2 Acute) is important and 352/IBD can also help set the stage for the big dance.

If anyone thinks we've lost value by not going to P3 with a 7 year chronic drug ... let's see what you think when they pull 20 year protections in various respects.  That's my sprots bet.

[StockingUp21]

False equivalence is a logical fallacy in which an equivalence is drawn between two subjects based on flawed or false reasoning. This fallacy is categorized as a fallacy of inconsistency. Colloquially, a false equivalence is often called "comparing apples and oranges."  

[MrMugsy]

Let me draw equivalence for you ... stockings = stutters Are you taking the bet or are you too scared ? : )

[StockingUp21]

again projection. You are proveto have more alias. I am not studders or anyone.  it's not right to talk about a reputabl pharma in the same sentence as this one until they are proven. False equivalence. 

[MrMugsy]

OK - kindly talk to an amazing Phase 2A and 2B and tell me how you see it relating to acute pain. Tell me how you thing ATE is going to solve chronic Wait - on second thought ... don’t. Already placed my bets and I’m thinking way beyond your fears. past 352 and cancer pain ... past metastasis ... past IBD and all the wonderful angles there. Im on 340 and future drug delivery. so ... am

[Chianchin]

You are a fool living in fools dream, the pharma industry understand and select the best class companies with high potential. ATE would not be trading at $.68 cents if the potential sales for the new dug was in the billion. Big pharma would be buying shares and taking majority staakes in ATE.  Do you think you are smarter than the biotech industry in understanding biotech potential? I know

[StockingUp21]

Ok so you want to deflect from your alias and projection thread Does all trails that pass 2a and b go get approved? What about the next trial that failed. This has to be done all over again right be honest

[MrMugsy]

WHat about the pause?  It’s a learning opportunity. I’m not afraid of it - makes us stronger ! Thank your lucky stars we caught it before P3 and now we’re looking at 20 year IP. Im going to leave it at that. This is the wrong place for fear of development hurdles with a drug development company. In or Out ?  That’s all you have to worry about!

[Chianchin]

The overall market that involves hundreds of biotech expert investors togheter are far more astute than failled investor mugsy.  ATE at $.68 ceents indicate that the market doe not give ATE a lot of potetnail.Again Mugsy, in which company that you pumped for 8 years have you mde profits. Let me think......0........ let me spell it zero. ATE, GUD, PRN all in the dog house and all time lows

[Chianchin]

What an id iot? BMS has one of the largeste new dug pipeline among all big pharma do your DD. BLA..bla mugsy. If ATE PHASE 2 drug potential  in the future was in the billions the shares price would not be trading at $.68 as large pharmas would be all over ATE.  Mugsy bought ATE  at $5 and now needs you readers to bail him out of his  huge financial miseries. Mugsy can youu name

[themagicbox]

Bery interesting. Whats most surprising is that Immatics was able to secure these billions of dollars despite none of their pipeline IP being past Ph1. And most of the IP secured by Bristol is still in preclinical stages. I really want to say ATE is lagging because of its size, poor captial market exposure (canada is very poor in that regard), and a meek CEO. But how can ATE not be farther ahead

[themagicbox]

for reference: https://immatics.com/our-pipeline/

[MrMugsy]

Thanks Magic. Exactly !!!! That's telling where our potential is. If they can get that kind of a deal - It just adds to the way we can negotiate going forward - on good news. The tide will turn - in our favor - as it's done in the past - just going to hit higher and harder the next time.  Please quote me on that in the future.  I'd rather have a regular quote me than a

[MrMugsy]

In my opinion ... it's just perception and I think that all changes when people see what we really have here.  Just takes time.  There is some real science to get through right now - then we'll see what happens.